Big data, machine learning and drug discovery in oncology By glyn|2021-02-10T11:09:33+00:00February 10th, 2021|media|0 Comments Read More
Targeting a KRAS neoantigen peptide vaccine to DNGR-1+ dendritic cells By glyn|2021-02-10T11:07:27+00:00February 10th, 2021|media|0 Comments Read More
Predicting outcomes of systemic therapy in advanced cancers using circulating tumour DNA dynamics By glyn|2021-02-10T11:04:58+00:00February 10th, 2021|media|0 Comments Read More
Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor By glyn|2021-02-10T10:41:39+00:00February 10th, 2021|media|0 Comments Read More
VHL/HIF and VEGF inhibitors in clear cell renal cell carcinoma By glyn|2021-02-09T15:17:48+00:00February 9th, 2021|media|0 Comments Read More
Prospective validation of single mouse testing by the paediatric preclinical testing consortium By glyn|2021-02-09T15:14:43+00:00February 9th, 2021|media|0 Comments Read More
Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients By glyn|2021-02-09T15:12:40+00:00February 9th, 2021|media|0 Comments Read More
The ENA virtual meeting 2020: Dr. Toni Choueiri By glyn|2021-02-09T15:15:02+00:00February 9th, 2021|media|0 Comments Read More
Adagrasib in advanced/metastatic NSCLC with KRAS G12C mutation By glyn|2021-02-09T15:08:22+00:00February 9th, 2021|media|0 Comments Read More
Development of novel inhibitors of KRASG12C By glyn|2021-02-09T15:04:43+00:00February 9th, 2021|media|0 Comments Read More
